From ADC to XDC: Exploring the new wave of bioconjugate drugs

As antibody-drug conjugates (ADCs) continue their rapid rise, the industry is entering an exciting new era with the emergence of bioconjugates that extend beyond traditional ADCs. While these novel modalities offer tremendous promise, they also bring a distinct set of challenges throughout the drug development journey.

When compared to ADCs, Antibody–Oligonucleotide Conjugates (AOCs) and other bioconjugate modalities face unique challenges in their early development stages. Preparation, analysis, and both in vitro and in vivo studies are particularly critical.

Join us for this insightful webinar as our expert speaker shares valuable perspectives and real-world case studies on AOCs. You will also discover how WuXi XDC’s integrated discovery services accelerate early development for bioconjugate.

Key Learning Objectives

• The evolving landscape of bioconjugate development
• Key updates on AOC research and development
• Real world case studies on AOC discovery
• Accelerating Bio-Conjugate Discovery through WuXi XDC’s Integrated Service Platform

Presenters
Dr. Jiawei Lu, Head of Bio-Conjugation Discovery Services / Sr. Director, WuXi XDC